Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
about
Crizotinib: A comprehensive reviewMolecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerThe distinctive nature of adenocarcinoma of the lungAnaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Cytogenetic findings in lung cancer that illuminate its biological history from adenomatous hyperplasia to bronchioalveolar carcinoma to adenocarcinoma: A case reportSignificance of persistent inflammation in respiratory disorders induced by nanoparticlesCrizotinib-Induced Abnormal Signal Processing in the RetinaALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing CountryClinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Generation and repair of AID-initiated DNA lesions in B lymphocytes.The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genomeFusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionRecent advances in immunotherapy for non-small-cell lung cancer.Volatile fingerprints of cancer specific genetic mutations.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsActivity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutationTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screeningMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.The potential for crizotinib in non-small cell lung cancer: a perspective reviewPersonalizing therapy with targeted agents in non-small cell lung cancerAn integrated molecular modeling approach for in silico design of new tetracyclic derivatives as ALK inhibitors.Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung canceOptimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.The role of molecular analyses in the era of personalized therapy for advanced NSCLC.EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancerRearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors.Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screeningGround-glass nodule in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-positive lung cancer: a case report.Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.Ultradense array CGH and discovery of micro-copy number alterations and gene fusions in the cancer genome.Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.Destaining of Diff-Quik stained cytologic smears is not necessary for the detection of anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma by fluorescence in situ hybridizationStatus of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma.Ovarian metastasis from non-small cell lung cancer with ALK and EGFR mutations: A report of two cases.Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
P2860
Q24624083-5A5D6BC7-10FB-4662-B907-C62E4A9D9C85Q26771116-3540C0E1-F385-4F37-865D-FFA6FBE8962DQ26781159-62FF7D7D-01B4-421E-819D-9866B70640A1Q27851588-A70B7A52-73A9-4750-8C34-63F6C3A505E8Q28281176-0B06D43B-BB1F-4FE1-A3E8-23241CAD7219Q28390890-D2C6BEFB-57BB-4C53-92D5-3F33110F1DAFQ28547218-468D371B-B76F-4770-A6FC-F27DCF0B8EDEQ28554218-CD4EF8AD-FB9E-42B9-93C2-2DCCED330ECBQ31167585-9571C5A9-053F-44DD-ACF0-050717BBFF24Q33690522-342E878E-69D3-4CB0-A91F-05D9F1F76E59Q33805565-6A8C1683-8E4C-4697-8878-CC2CB60BDDD8Q34013976-E2389DE0-E97E-4E7C-8986-2477BB385210Q34290801-4B5053CA-72C6-4C34-A22C-CCB670FCA9BBQ34293462-A37C5EF0-ED67-45DD-B55E-190F0A532600Q34564071-84C8AD12-8723-4798-87C6-C2609341FBDBQ34743127-15DC9C51-406C-485C-913C-317BD9500358Q34938204-6DCB26A5-BA84-46E1-BE0D-F39E2B33F182Q35131017-D7884D50-B64A-4882-B99E-C64FFD085EB6Q35136424-BA57585D-BDC3-4278-A5C3-7E268170E975Q35208584-87041370-FE8F-40FF-8C6F-9BF9C13F15C2Q35534514-F9294B44-3B14-4923-ADAD-58FAA4CC85A9Q35679361-222EE839-66F1-49DB-8F89-49B4B23804D6Q35892197-8D653A85-88DC-4FAD-912C-697954BFB7F6Q35928667-D2683C91-6E14-49C3-B217-53BB65BD9962Q36090684-E090D8D2-96CB-44F7-8D19-D55E685299BFQ36111972-058B138C-B29D-4F15-B480-B96D7EB1304AQ36244073-BB05BFF9-B0EB-4061-A11B-A905955E3BDEQ36260477-C80E55B4-F7D7-4F69-9B68-4082E0514208Q36365622-8B032D23-6107-46AC-949C-3D374F8167BCQ36414458-2F8B9454-C3A0-4EC5-BF68-441E401BEA52Q36671621-819612AF-FA9B-44F7-883A-47A896F5895CQ36929734-FF850C34-D113-48E6-8F46-EB03868ABF64Q36954610-38D59D08-93E1-4BC3-A08C-481D58AD224CQ36996220-79F2EDF4-A338-4CFB-A766-B366196AE011Q37164587-22FB5AB7-D578-4197-9C54-BE12A4A65084Q37199755-D3DD020C-136C-4817-BD2C-03E8734BD9F1Q37232769-F2A2F5B6-1ECE-4698-8FC8-D7308314D3EAQ37582099-9C8B04F8-8723-4E45-BDC7-F1055F98ACFEQ37604076-D107BA70-ABC4-4957-9D9E-A0B931B50670Q37606591-96B35588-2074-408B-B996-20A70FFBFF24
P2860
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
@ast
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
@en
type
label
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
@ast
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
@en
prefLabel
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
@ast
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
@en
P1433
P1476
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
@en
P2093
Hiroyuki Mano
P2860
P304
P356
10.1111/J.1349-7006.2008.00972.X
P577
2008-11-20T00:00:00Z